Добірка наукової літератури з теми "Subcutaneous delivery"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Subcutaneous delivery".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Subcutaneous delivery"
Dychter, Samuel S., David A. Gold, and Michael F. Haller. "Subcutaneous Drug Delivery." Journal of Infusion Nursing 35, no. 3 (2012): 154–60. http://dx.doi.org/10.1097/nan.0b013e31824d2271.
Повний текст джерелаBenagiano, Giuseppe, Henry Gabelnick, and Manuela Farris. "Contraceptive devices: subcutaneous delivery systems." Expert Review of Medical Devices 5, no. 5 (September 2008): 623–37. http://dx.doi.org/10.1586/17434440.5.5.623.
Повний текст джерелаHoutzagers, C. M. G. J. "Subcutaneous Insulin Delivery: Present Status." Diabetic Medicine 6, no. 9 (December 1989): 754–61. http://dx.doi.org/10.1111/j.1464-5491.1989.tb01274.x.
Повний текст джерелаSelvaraj, Jothy, Graham Rhall, Mounir Ibrahim, Talat Mahmood, Nigel Freeman, Zennon Gromek, Grant Buchanan, Farhan Syed, Hany Elsaleh, and Ben J. C. Quah. "Custom-designed Small Animal focal iRradiation Jig (SARJ): design, manufacture and dosimetric evaluation." BJR|Open 2, no. 1 (November 2020): 20190045. http://dx.doi.org/10.1259/bjro.20190045.
Повний текст джерелаMapletoft, John W., Laura Latimer, Lorne A. Babiuk, and Sylvia van Drunen Littel-van den Hurk. "Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies." Clinical and Vaccine Immunology 17, no. 1 (October 28, 2009): 23–35. http://dx.doi.org/10.1128/cvi.00250-09.
Повний текст джерелаYamasaki, Yoshimitsu. "Subcutaneous and transmucosal delivery of insulin." Drug Delivery System 15, no. 6 (2000): 525–32. http://dx.doi.org/10.2745/dds.15.525.
Повний текст джерелаJones, Graham B., David S. Collins, Michael W. Harrison, Nagarajan R. Thyagarajapuram, and Justin M. Wright. "Subcutaneous drug delivery: An evolving enterprise." Science Translational Medicine 9, no. 405 (August 30, 2017): eaaf9166. http://dx.doi.org/10.1126/scitranslmed.aaf9166.
Повний текст джерелаYang, M. X., B. Shenoy, M. Disttler, R. Patel, M. McGrath, S. Pechenov, and A. L. Margolin. "Crystalline monoclonal antibodies for subcutaneous delivery." Proceedings of the National Academy of Sciences 100, no. 12 (June 2, 2003): 6934–39. http://dx.doi.org/10.1073/pnas.1131899100.
Повний текст джерелаAnderson, David R., Jeffrey S. Ginsberg, Robert Burrows, and Pat Brill-Edwards. "Subcutaneous Heparin Therapy during Pregnancy: a Need for Concern at the Time of Delivery." Thrombosis and Haemostasis 65, no. 03 (1991): 248–50. http://dx.doi.org/10.1055/s-0038-1647659.
Повний текст джерелаDirnena-Fusini, Ilze, Marte Kierulf Åm, Anders Lyngvi Fougner, Sven Magnus Carlsen, and Sverre Christian Christiansen. "Intraperitoneal, subcutaneous and intravenous glucagon delivery and subsequent glucose response in rats: a randomized controlled crossover trial." BMJ Open Diabetes Research & Care 6, no. 1 (November 2018): e000560. http://dx.doi.org/10.1136/bmjdrc-2018-000560.
Повний текст джерелаДисертації з теми "Subcutaneous delivery"
Al, Kurdi Zakieh. "Subcutaneous and oral delivery of insulin." Thesis, University of Greenwich, 2015. http://gala.gre.ac.uk/18146/.
Повний текст джерелаFaraji-Rad, Zahra. "Microneedles fabrication for subcutaneous fluid sampling and drug delivery." Thesis, University of Birmingham, 2016. http://etheses.bham.ac.uk//id/eprint/6734/.
Повний текст джерелаDeadman, Claire Michelle. "Biopharmaceutical studies of slow release, subcutaneous polymeric drug delivery systems." Thesis, University College London (University of London), 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433154.
Повний текст джерелаMarquette, Sarah. "Stabilization and development of sustained-release formulations of protein/antibody for subcutaneous delivery." Doctoral thesis, Universite Libre de Bruxelles, 2014. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209251.
Повний текст джерелаThis project aimed at developing a drug delivery system (DDS) able to enhance the stability and
residence time in vivo of antibodies (Abs). The system will deliver drug by the subcutaneous
route (SC), while ensuring accurate control of the drug release and the resulting plasmatic level. This technology platform will allow to reduce frequency of injection, potentially decrease side effects and maintain high concentration of Abs which will improve life of patient having chronic disease such as autoimmune and inflammatory disease. Biodegradable synthetic polymer-based formulations (polylactide-co-glycolide (PLGA)) were selected as carriers for encapsulated Abs. This was because they offer good protection for the Abs and allow sustained release of the Abs for a controlled period of time. After the evaluation of different encapsulation methods such as the water-oil-in-water (w/o/w) and the solid-in-oil-inwater
(s/o/w) processes, the encapsulation of the Ab in solid state (s/o/w) appeared to be more appropriate for producing Ab-loaded PLGA microspheres (MS). It allowed us to maintain the
Ab in a monomeric conformation and to avoid the formation of unsoluble aggregates mainly present at the water/oil interface. The first part of the project was the optimization of both the method for producing the Ab solid particles (spray-drying process) and the encapsulation of these Ab solid particles into the polymeric MS (s/o/w process) by design of experiment (DoE). These optimizations were carried out using a bovine polyclonal immunoglobulin G (IgG) as model molecule. In further optimization of the spray-drying process by (DoE), aqueous Ab solutions were spray-dried using a mini Spray-Dryer assembly with a 0.7 mm spray nozzle. In accordance with the particle size (d(0.5) ~5 μm), the stability (no loss of monomer measured by
size exclusion chromatography (SEC) and the yield of the spray-drying process (> 60 % w/w), the process parameters were set of follow: 3 mL/min as liquid feed flow rate, 130°C /75°C as inlet temperature (inlet T°) / outlet temperature (outlet T°), 800 L/h as atomization flow rate and
30 m3/h as drying air flow rate. For the s/o/w, the methylene chloride (MC) commonly used for
an encapsulation process was replaced by ethyl acetate (EtAc), which was considered as a more
suitable organic solvent in terms of both environmental and human safety. The effects of several processes and formulation factors were evaluated on IgG:PLGA MS properties such as: particle size distribution, drug loading, IgG stability, and encapsulation efficiency (EE%). Several formulations and processing parameters were also statistically identified as critical to get reproducible process (e.g. the PLGA concentration, the volume of the external phase, the emulsification rate, and the quantity of IgG microparticles). The optimized encapsulation
method of the IgG has shown a drug loading of up to 6 % (w/w) and an encapsulation efficiency
of up to 60 % (w/w) while preserving the integrity of the encapsulated antibody. The produced MS were characterized by a d(0.9) lower than 110 μm and showed burst effect lower than 50 %(w/w). In the second part of the project, the optimized spray-drying and s/o/w processes
developed with the IgG were applied to a humanized anti-tumor necrosis factor (TNF) alpha
MAb to confirm the preservation of the MAb activity during these processes. The selected s/o/w method allowed us to produce MAb-loaded PLGA MS with an appropriate release profile up to 6 weeks and MAb stability. In order to maintain the Abs’ activity, both during encapsulation and
dissolution, the addition of a stabilizer such as trehalose appeared to be crucial, as did the
selection of the PLGA. It was demonstrated that the use of a PLGA characterized by a 75:25
lactide:glycolide (e.g. Resomer ® RG755S) ratio decreased the formation of low molecular weight species during dissolution, which led to preserve Abs activity through its release from the
delivery system. Furthermore, the release profile was adjusted according to the type of polymer
and its concentration. E.g. 10 % w/v RG755S allowed Ab MS with a release time of 6 weeks to
be obtained. The optimization of both the formulation and the encapsulation process allowed
maximum 13 % w/w Ab-loaded MS to be produced. It was demonstrated that the Ab-loaded PLGA MS were stable when stored at 5°C for up to 12 weeks and that the selection of the appropriate type of PLGA was critical to assuring the stability of the system. The better stability observed when using a PLGA characterized by a 75:25 lactide:glycolide ratio was attributed to
its slower degradation rate. Finally, the sustained release of Ab from the developed MS and the preservation of its activity was confirmed in vivo in a pharmacokinetic (pK) study realized in
rats. In conclusion, the application of the concept of entrapment into a polymer matrix for
stabilization and sustained release of biological compounds was demonstrated through this work.
RÉSUMÉ
Ce projet a pour but de développer un système de délivrance de médicament capable d’augmenter la stabilité et le temps de résidence in vivo des anticorps. Ce système sera administré par voie sous-cutanée et permettra un control précis de la libération du produit et de son niveau plasmatique. Cette plateforme technologique nous permettra de réduire la fréquence d’injection, de réduire potentiellement les effets secondaires et de maintenir des concentrations élevées en anticorps tout en améliorant la vie des patients atteints de maladies chroniques autoimmunes ou inflammatoires. Les formulations à base de polymères synthétiques, biodégradables (PLGA) ont été sélectionnés comme véhicules pour encapsuler les anticorps. Ils offrent en effet une bonne protection pour les anticorps and permettent une libération contrôlée de ceux-ci pendant une période définie. Après l’évaluation de différents méthodes d’encapsulation tels que les procédés d’eau-dans-huile-dans-eau (w/o/w) et solide-dans-huile-dans-eau (s/o/w), l’encapsulation des anticorps sous forme solide apparaissait plus apporpriée pour produire des microsphères de polymère chargées en anticorps. Cette technique nous permettait de maintenir l’anticorps sous sa forme monomérique et d’éviter la formation d’agrégats insolubles qui apparaissaient principalement à l’interface eau/huile. La première partie du projet a été d’optimiser à la fois la méthode nous permettant d’obtenir les anticorps sous forme de particules solides (spray-drying) et la méthode d’encapsulation de ces particules d’anticorps dans les microsphères de polymères. Cela a été réalisé par des plans d’expérience en utilisant une IgG bovine polyclonale comme molécule modèle. Durant l’optimisation du procédé de spray-drying,
les solutions aqueuses d’anticorps ont été atomisées en utilisant le mini Spray-Dryer assemblé avec une buse de pulvérisation d’un diamètre de 0.7 mm. En accord avec la taille particulaire (d(0.5) ~5 μm), la stabilité (absence de perte en monomère mesurée par chromatographie d’exclusion de taille et le rendement d’atomisation (> 60 % w/w), les paramètres d’atomisation ont été fixés: 3 mL/min pour le débit de liquide, 130°C /75°C pour la température d’entrée / température de sortie, 800 L/h pour le débit d’air d’atomisation et 30 m3/h pour le débit d’air de séchage. Pour le s/o/w, le dichlorométhane communément utilisé dans les procédés d’encapsulation a été remplacé par l’acétate d’éthyle qui est considéré comme un meilleure solvant organique en terme d’environnement et de sécurité. Les effets de plusieurs paramètres de fabrication ou de formulation ont été évalués sur les propriétés des microsphères polymériques d’anticorps (distribution de taille particulaire, taux de charge en anticorps, stabilité de l’anticorps et efficacité d’encapsulation). Plusieurs paramètres de fabrication et de formulation ont été statistiquement identifiés comme critiques pour obtenir un procédé reproductible (par exemple. La concentration en PLGA, le volume de phase externe, la vitesse d’émulsification et la quantité d’anticorps). La méthode d’encapsulation ainsi optimisée permettait d’obtenir un taux
de charge jusqu’à 6% (w/w) avec une efficacité d’encapsulation jusqu’à 60 % (w/w) tout en
préservant l’intégrité de l’anticorps encapsulé. Les microsphères produites étaient caractérisées
par un d(0.9) inférieur à 110 μm et montraient une libération après 24 h inférieure à 50 % (w/w).
Dans le seconde partie du projet, les procédés d’atomisation et d’encapsulation développés avec
l’IgG ont été appliqués à un anticorps monoclonal anti-TNF alpha humanisé pour confirmer la
conservation de l’activité de l’anticorps pendant ces procédés. La méthode s/o/w sélectionnée
permettait de produire des microsphères de PLGA chargées en anticorps avec un profil de libération jusqu’à 6 semaines et un maintien de la stabilité de l’actif. Afin de maintenir l’activité de l’anticorps, à la fois pendant le procédé d’encapsulation et pendant la libération, l’ajout d’un stabilisant tel que le tréhalose est apparu crucial ainsi que le choix du type de PLGA. Il a été démontré que l’utilisation du PLGA caractérisé par un ratio lactide :glycolide de 75 :25 (par exemple, Resomer ® RG755S) diminuait la formation d’espèces de faible poids moléculaire
pendant la dissolution. Cela contribuait à préserver l’activité de l’anticorps durant la libération à partir des microsphères. De plus, le profil de libération était modulé en fonction du type de polymère et de sa concentration. Par exemple, l’utilisation d’une solution à 10 % w/v RG755S conduisait à la production de microsphères d’anticorps avec un temps de libération sur 6
semaines. L’optimisation de la formulation et du procédé d’encapsulation a permis de produire
des microsphères avec des taux de charge en anticorps de maximum 13 % w/w. Il a été démontré
que ces microsphères, stockées à 5°C, étaient stables jusqu’à 12 semaines et que la sélection du
type de PLGA était critique pour assurer la stabilité du système. La meilleure stabilité a été
obtenue en utilisant le PLGA caractérisé par un ratio lactide :glycolide de 75 :25. Cela a été
attribué à sa plus faible vitesse de dégradation. Enfin, la libération contrôlée de l’anticorps à
partir de ces microsphères et la conservation de son activité ont été confirmées in vivo lors d’une
étude pharmacocinétique réalisée chez le rat. En conclusion, ce travail a permis de démontrer
l’application du concept d’ « emprisonnement » des composés biologiques dans des matrices
polymériques afin de les stabiliser et contrôler leur libération.
Doctorat en Sciences biomédicales et pharmaceutiques
info:eu-repo/semantics/nonPublished
Carlier, Emeric. "Development of 3D printed implants for subcutaneous administration of sustained-release antibodies." Doctoral thesis, Universite Libre de Bruxelles, 2021. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/326756.
Повний текст джерелаDoctorat en Sciences biomédicales et pharmaceutiques (Pharmacie)
info:eu-repo/semantics/nonPublished
Edwards, Eric. "DEVELOPMENT OF A NOVEL APPROACH TO ASSESS QUALITATIVE AND QUANTITATIVE DYNAMICS ASSOCIATED WITH THE SUBCUTANEOUS OR INTRAMUSCULAR ADMINISTRATION OF PHARMACEUTICALS AND ASSOCIATED PARENTERAL DELIVERY SYSTEMS." VCU Scholars Compass, 2011. http://scholarscompass.vcu.edu/etd/279.
Повний текст джерелаZhi, Kaining. "Formulation and Fabrication of a Novel Subcutaneous Implant for the Zero-Order Release of Selected Protein and Small Molecule Drugs." Diss., Temple University Libraries, 2017. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/482373.
Повний текст джерелаPh.D.
Diabetes is a leading cause of death and disability in the United States. Diabetes requires a lifetime medical treatment. Some diabetes drugs could be taken orally, while others require daily injection or inhalation to maximize bioavailability and minimize toxicity. Parenteral delivery is a group of delivery routes which bypass human gastrointestinal track. Among all the parenteral methods, we chose subcutaneous implant based on its fast act and high patient compliance. When using subcutaneous implant, drug release needs to be strictly controlled. There are three major groups of controlled release methods. Solvent controlled system is already used as osmotic implant. Matrix controlled system is used in Zoladex® implant to treat cancer. Membrane controlled systems is widely used in coating tablets, but not that popular as an implant. Based on the research reported by previous scientists, we decided to build a hybrid system using both matrix and membrane control to delivery human insulin and other small molecule drugs. Subcutaneous environment is different from human GI track. It has less tolerance for external materials so many polymers cannot be used. From the FDA safe excipient database, we selected albumin as our primary polymer and gelatin as secondary choice. In our preliminary insulin diffusion study, we successfully found that insulin mixed with albumin provided a slower diffusion rate compared with control. In addition, we added zinc chloride, a metal salt that can precipitate albumin. The insulin diffusion rate is further reduced. The preliminary study proved that matrix control using albumin is definitely feasible and we might add zinc chloride as another factor. In order to fabricate an implant with appropriate size, we use lyophilisation technology to produce uniformly mixed matrix. Apart from albumin and human insulin, we added sucrose as protectant and plasticizer. The fine powder after freeze-dry was pressed as a form of tablet. The tablets were sealed in Falcon® cell culture insert. Cell culture insert provide a cylinder shape and 0.3 cm2 surface area for drug release. Insulin release study provided a zero order kinetics from prototypes with zinc chloride or 0.4 micron pore size membrane. Caffeine was used as a model drug to investigate the releasing mechanism. Three pore size membranes (0.4, 3 and 8 micron) were tested with same formulation. While 0.4 micron prototypes provided the slowest release, 3 micron ones surprisingly released caffeine faster than 8 micron implants. We calculated the porosity with pore size and concluded that the percentage of open area on a membrane is the key point to control caffeine release. 0.4 micron membranes were used for future research. We increased the percentage of albumin in our excipient, and achieved a slower caffeine release. However, the zero order release could only last for 3 days. After we replaced sucrose with gelatin, a 5 day zero order release of caffeine was achieved. With all the results, we proposed our “Three Phase” drug release mechanism controlled by both membrane and matrix. Seven other small molecule drugs were tested using our prototype. Cloudy suspension was observed with slightly soluble drugs. We updated our “Three Phase” drug release mechanism with the influence of drug solubility. Data shows that releasing rate with same formulation and membrane follows the solubility in pH 7.4. This result proves that our prototype might be used for different drugs based on their solubility. Finally, with all the information of our prototype, we decided to build a “smart insulin implant” with dose adjustment. We proposed an electrical controlled implant with different porosity membranes. Solenoid was used as the mechanical arm to control membrane porosity. 3-D printing technology was used to produce the first real prototype of our implant. Finally, insulin implant with clinically effective insulin release rate was achieved.
Temple University--Theses
Mohangi, Govindrau Udaibhan. "Comparative study of heterotopic bone induction using porcine bone morphogenetic proteins delivered into the rodent subcutaneous space with allogeneic and xenogeneic collagen carriers." Diss., 2009. http://hdl.handle.net/2263/25476.
Повний текст джерелаКниги з теми "Subcutaneous delivery"
Sylvestervich, Andrea. A manual for subcutaneous infusion pumps at Kingston General Hospital and Kingston Regional Cancer Centre. [Kingston, Ont.]: Kingston General Hospital, 1990.
Знайти повний текст джерелаKang, David W., and Renee Tannenbaum. ENHANZE® Drug Delivery Technology: Advancing Subcutaneous Drug Delivery Using Recombinant Human Hyaluronidase PH20. Karger AG, S., 2022.
Знайти повний текст джерелаKang, David W., and Renee Tannenbaum. ENHANZE® Drug Delivery Technology: Advancing Subcutaneous Drug Delivery Using Recombinant Human Hyaluronidase PH20. Karger AG, S., 2022.
Знайти повний текст джерелаЧастини книг з теми "Subcutaneous delivery"
Scioli Montoto, Sebastian, and Maria Esperanza Ruiz. "Subcutaneous Drug Delivery." In The ADME Encyclopedia, 1107–14. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-84860-6_100.
Повний текст джерелаScioli Montoto, Sebastian, and Maria Esperanza Ruiz. "Subcutaneous Drug Delivery." In The ADME Encyclopedia, 1–8. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-51519-5_100-1.
Повний текст джерелаHovorka, Roman. "Closing the loop." In Oxford Textbook of Endocrinology and Diabetes, 1869–74. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.1455.
Повний текст джерелаBittner, Beate, and Johannes Schmidt. "Subcutaneous drug delivery devices—Enablers of a flexible care setting." In Drug Delivery Devices and Therapeutic Systems, 159–79. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-12-819838-4.00021-3.
Повний текст джерелаHovorka, Roman, and Charlotte Boughton. "“Closed Loop” Insulin Delivery." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple, 2071–76. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0264.
Повний текст джерелаSaltzman, W. Mark. "Controlled Drug Delivery Systems." In Drug Delivery. Oxford University Press, 2001. http://dx.doi.org/10.1093/oso/9780195085891.003.0015.
Повний текст джерелаSahu, Anil Kumar, Vishal Jain, Gyanil Kumar Sahu, Saraswati Prasad Mishra, Koushlesh Mishra, Vaibhav Tripathi, Shweta Dutta, and Pankaj Kashyap. "Recent Advancement to Improve Intestinal Absorption of Macromolecular Drugs." In Advancements in Controlled Drug Delivery Systems, 237–56. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-8908-3.ch010.
Повний текст джерелаCrepeau, Amy Z. "Neuropharmacology." In Mayo Clinic Neurology Board Review, edited by Kelly D. Flemming, 215–24. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197512166.003.0027.
Повний текст джерелаBurnette, Michelle S., Laura Roland, Everett Chu, and Marianne David. "Alternative Regional Anesthetic Techniques." In Obstetric Anesthesia Practice, 174–85. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190099824.003.0014.
Повний текст джерелаPickup, John, and Nick Oliver. "Glucose Monitoring and Sensing." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple, 1975–78. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0251.
Повний текст джерелаТези доповідей конференцій з теми "Subcutaneous delivery"
Jones, Richard W., and Francesco Gianni. "Subcutaneous versus intra-peritoneal insulin delivery in the artificial pancreas." In 2018 13th IEEE Conference on Industrial Electronics and Applications (ICIEA). IEEE, 2018. http://dx.doi.org/10.1109/iciea.2018.8397770.
Повний текст джерелаPark, Eun-Joo, Jeff Dodds, Nadine Barrie Smith, Kullervo Hynynen, and Jacques Souquet. "Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection." In 9TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND: ISTU—2009. AIP, 2010. http://dx.doi.org/10.1063/1.3367167.
Повний текст джерелаDungel, Paul, Yvonne Moussy, and Lawrence Hersh. "Two Methods of Determining [3H]Dexamethasone Distribution in Rat Subcutaneous Tissue." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-172803.
Повний текст джерелаShi, Jing, Pouyan Mohajerani, Stefan Morscher, Wouter Driessen, Neal Burton, Daniel Razansky, and Vasilis Ntziachristos. "Abstract 58: Comparative determination of compound delivery to orthotopic and subcutaneous tumors by non-invasive imaging." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-58.
Повний текст джерелаChaudhuri, Buddhadev P., F. Ceyssens, S. Celen, G. Bormans, M. Kraft, and R. Puers. "In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration *." In 2019 41st Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2019. http://dx.doi.org/10.1109/embc.2019.8857543.
Повний текст джерелаWang, Bin, Hui Hu, Ayodeji Demuren, and Eric Gyurcsko. "Experimental and Theoretical Studies of Pulsed Micro Flows Pertinent to Continuous Subcutaneous Insulin Infusion (CSII) Therapy." In ASME 2010 3rd Joint US-European Fluids Engineering Summer Meeting collocated with 8th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2010. http://dx.doi.org/10.1115/fedsm-icnmm2010-30303.
Повний текст джерелаWorley, Deanna R., Ryan J. Hansen, Laura S. Chubb, and Daniel L. Gustafson. "Abstract B48: Subcutaneous delivery of docetaxel and carboplatin accumulate preferentially in lymphatic circulation as compared to intravenous delivery in rats with surgically created lymph and venous fistulae." In Abstracts: AACR Special Conference: The Translational Impact of Model Organisms in Cancer; November 5-8, 2013; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1557-3125.modorg-b48.
Повний текст джерелаZedelmair, Michael M., and Abhijit Mukherjee. "Numerical Simulation of Insulin Depot Formation in Subcutaneous Tissue Comparing Different Cannula Geometries." In ASME 2016 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/imece2016-67473.
Повний текст джерелаBUXTON, DE, BJ CHILDERS, and KC OBERG. "A NOVEL METHOD TO ENHANCE THE SUBCUTANEOUS DETECTION OF BIOLUMINESCENCE IN THE FACULTATIVE ANAEROBE, STREPTOCOCCUS PYOGENES, BY DMSO-ASSISTED TRANSDERMAL OXYGEN DELIVERY." In Proceedings of the 13th International Symposium. WORLD SCIENTIFIC, 2005. http://dx.doi.org/10.1142/9789812702203_0088.
Повний текст джерелаMeschengieser, S. S., A. I. Woods, and M. Z. Lazzari. "ANTICOAGULATION IN PREGNANCY IN PATIENTS WITH CARDIAC VALVE PROSTHESIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643266.
Повний текст джерелаЗвіти організацій з теми "Subcutaneous delivery"
Expanding access and method choice: Evidence of client self-administration of injectables and private sector provision of family planning services in three West African countries. Population Council, 2020. http://dx.doi.org/10.31899/sbsr2020.1003.
Повний текст джерела